



OTCQB: GNVR

Peptides by Design™

March 2026

Corporate Overview & Investor Presentation



Forward Looking Statements



This presentation contains "forward-looking statements." The statements contained in this presentation that are not purely historical are forward-looking statements. Forward-looking statements give the Company's current expectations or forecasts of future events. Such statements are subject to risks and uncertainties that are often difficult to predict and beyond the Company's control and could cause the Company's results to differ materially from those described. In some cases, forward-looking statements can be identified by terminology such as "may," "should," "potential," "continue," "expects," "anticipates," "intends," "plans," "believes," "estimates," and similar expressions. These statements include statements regarding moving forward with executing the Company's global growth strategy. The statements are based upon current beliefs, expectations and assumptions and are subject to a number of risks and uncertainties, many of which are difficult to predict. The Company is providing this information as of the date of this presentation and does not undertake any obligation to update any forward-looking statements contained in this presentation as a result of new information, future events or otherwise, except as required by law. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends affecting the financial condition of our business. Forward-looking statements should not be read as a guarantee of future performance or results and will not necessarily be accurate indications of the times at, or by, which such performance or results may be achieved.

Genvor is on a Mission to Transform Agriculture and Human Health & Wellness Through its AI-Accelerated Peptide Platform



Dr. Jesse Jaynes, Ph.D.



Dr. Clayton C. Yates, Ph.D.

The Founders' Vision

Dr. Jesse Jaynes and Dr. Clayton Yates, leading experts in therapeutic and agricultural peptides, had a bold vision: If peptides could revolutionize human medicine by targeting diseases with precision and safety, why couldn't they transform agriculture? And if the same AI-accelerated platform could design peptides optimized for plants, what if it could also generate peptides optimized for human recovery, performance, anti-aging, and daily wellness?



In 2018, they founded Genvor with a bold vision: engineer peptides that optimize outcomes across agriculture and human health, using AI to accelerate discovery beyond what traditional R&D could achieve alone.

Today, Genvor is generating peptide solutions to boost yields, cut chemical use, and secure a sustainable food future, while bringing science-backed peptide innovation to human health and wellness.

Agriculture Faces a \$220 Billion Crisis



There's a significant opportunity to leverage peptides to defend against devastating plant pathogens while optimizing agricultural performance.

- ◆ Food production must double by 2050 to meet the food demand of the global population growth to 9.6 billion people¹.

- ◆ Annual global crop losses due to plant pathogens exceeds \$220 billion².
 - ◆ These include fungi such as “Aspergillus flavus,” which produce Aflatoxins – a toxic and carcinogenic compound known for liver cancer in humans and animals.
 - ◆ The annual cost of Aflatoxin contamination in the US alone is estimated to be ~\$500 million³.



Genvor's AI-accelerated platform yields peptides that address agriculture's most critical needs: enhanced productivity, regulatory compliance, and consumer safety.

The Agricultural Biologicals Market is Growing Rapidly with Regulatory Tailwinds



Traditional Ag chemical growth is peaking and faces regulatory headwinds, while **Biochemicals are in the beginning stages of a generational breakout.**

Peptide Regulatory Advantage

- ✓ Fast-track EPA registration (1 year vs 3 years)
- ✓ Simplified registration in many countries
- ✓ Increasing regulations favor biochemicals over synthetic chemicals
- ✓ Export exemptions from pesticide residue limits
- ✓ Compatible with organic certification requirements


Strategic Opportunity

Genvor's peptide technology aligns well with market shift toward biological fungicide solutions

Agricultural Biologicals Market¹

(\$ Billions)

Agricultural biologicals market projected to more than double from \$9.5B to \$19.7B with 11% CAGR



¹ Agricultural Biologicals Market - Forecasts from 2021 to 2026, Research & Markets

Consumer Peptide Market is Experiencing Strong Growth with Favorable Regulatory Pathways



Rising consumer demand for science-backed recovery, performance, and wellness solutions is driving rapid expansion of the global peptide supplements market.

OTC Regulatory Advantage

- ✔ OTC/supplement pathway faster and less capital-intensive than pharmaceutical approval
- ✔ No FDA drug approval required for wellness product positioning
- ✔ Growing regulatory acceptance of peptide-based supplements


Strategic Opportunity

Genvor's BioCypher platform generates peptide candidates optimized for human bioavailability, recovery, and performance.

Direct-to-consumer model enables faster revenue generation with higher margins than agricultural licensing.

Global Peptide Supplements Market¹

(\$ Billions)



¹ Industry analyst projections, 2025

Genvor Corporate Overview



Genvor is a biotechnology company harnessing AI to generate novel peptides that deliver high-performance solutions across agriculture and human health



Key Value Drivers

- ✓ AI-Accelerated platform
- ✓ Cross-crop and market scalability
- ✓ Compatible by design
- ✓ Flexible application methods



Strategic Adoption Model

- ✓ Scalability is accelerated through partnerships and licensing, enabling efficient market entry
- ✓ Direct-to-consumer model in human health brings targeted peptide-based recovery and performance solutions to market through strategic partnerships and retail channels.
- ✓ Actively engaged with multiple organizations for JVs & commercialization



Competitive Advantages

- ✓ Proprietary BioCypher platform with a library of millions of designed peptides
- ✓ 5 issued U.S. patents, 2 pending U.S. patent applications, and 4 additional applications in preparation
- ✓ Backed by 7+ years of USDA collaboration and 40+ years of combined academic and commercial expertise.



Market Opportunity

- ✓ **\$220 billion** in annual crop losses to plant pathogens globally
- ✓ Consumer peptide supplements market projected to reach **\$11.2 billion** by 2035

Genvor's Peptides are Designed for a Variety of Delivery Modes Across Agriculture and Human Health



Biological Sprays

Used for greenhouse and specialty crops like berries, herbs, and vegetables.


- ✓ Eco-friendly disease control
- ✓ Fast-track EPA registration
- ✓ Compatible with organic certification
- ✓ ~95% of plant diseases are caused by fungi & bacteria



Seed Traits

Peptides encoded directly into seeds of large-scale crops like corn, soybeans, and cotton.

- ✓ Long-term disease resistance
- ✓ Enhanced protein and nutrition
- ✓ Scalable through licensing partners



OTC Delivery

Peptides formulated for nasal delivery and other formats

- ✓ No Rx required
- ✓ Targeted recovery and performance support
- ✓ DTC and specialty retail distribution

Genvor's Competitive Advantage: The BioCypher™ Platform



Genvor's digitized peptide library of millions of peptides represents a breakthrough opportunity to efficiently generate peptides across agriculture and human health faster than anyone else



Proprietary Research Foundation

30+ years of peptide research across agriculture and human health creates the world's largest proprietary peptide dataset



Custom Algorithm Architecture

Genvor's proprietary peptide language and classification system powers AI-generated solutions across agriculture and human health




Unmatched Library Scale

Millions of designed peptides with proven efficacy data that competitors cannot replicate



Real-World Validation

AI trained on actual field performance and biological response data, not theoretical models or limited lab data



Our Four Core Peptide Technologies



At the heart of our innovation are four proprietary peptide classes that we engineer for high-impact applications in plant health, animal feed, and sustainable agriculture.



Antimicrobial Peptides (AMPs)

- ✓ **Purpose:** To prevent plant disease at the cellular level.
- ✓ **Mechanism:** AMPs work by inhibiting pathogens through targeted cellular interaction, replacing the need for chemical fungicides.
- ✓ **Benefits:** AMPs offer a residue-free alternative to traditional fungicides and are compatible with seed traits, seed treatments, and foliar applications.



C-terminally Encoded Peptides (CEPs)

- ✓ **Purpose:** To regulate plant growth, nutrient uptake, and stress response.
- ✓ **Mechanism:** Trigger plant receptor pathways that regulate nutrient uptake, stress response, and growth efficiency.
- ✓ **Benefits:** CEPs improve nutrient use efficiency, enhance stress tolerance, and strengthen the plant's immune system.



Insecticidal Peptides

- ✓ **Purpose:** To neutralize and sterilize insect pests by disrupting core biological systems.
- ✓ **Mechanism:** Target insect ion channels and membranes, disrupting key functions to neutralize pests without harming beneficial species.
- ✓ **Benefits:** Targets pests with precision, protecting crops without harming pollinators or beneficial species.



Nutrient Enhancing Peptides (NEPs)

- ✓ **Purpose:** To boost nutrition and metabolism in crops and animal feed.
- ✓ **Mechanism:** Boost nutrient absorption and protein synthesis by enhancing plant metabolism and uptake efficiency.
- ✓ **Benefits:** NEPs increase protein quality, support micronutrient absorption, and improve overall metabolic performance in plants and animals.

Genvor Peptide Development Pipeline



Three AMP Families & One NEP Family in Active Development

Potential Strategic Partners Typically Begin to Express Interest in Transactions During These Stages

Crop		Peptide Family	R&D	Trait Development	Testing	Trait Validation	Regulatory Approval
Citrus	Anti-Pathogen	AGM-176 & AGM-179					
Corn	Anti-Pathogen	AGM-182 & GV-185/187					
	Enhanced Nutrition	GV-HNP-1 & 2					
Rice	Anti-Pathogen	GV-185 & GV-187					
Soybean	Anti-Pathogen	GV-185 & GV-187					
Flax	Anti-Pathogen	GV-185 & GV-187					
Potato	Anti-Pathogen	GV-185 & GV-187					
Cotton	Anti-Pathogen	GV-185 & GV-187					

Already Secured Post-Approval Citrus Licensing Deal for AGM-176/179 with Tier-1 Partner

First Corn AMP advancing toward licensing readiness, enabled by USDA partnership

Legend

AMP
NEP

Lead Peptides Demonstrate Broad-Spectrum Efficacy Against Major Agricultural Pathogens

Genvor's synthetic peptide candidates demonstrated strong antifungal activity at low concentrations, de-risking the program for partnerships and commercial advancement

Design Generation	Synthetic Peptides							
	3rd		2nd		1st			
	GV185		GV187		AGM185		D4E1	
Fungal Pathogen	IC ₅₀ ^a	95% CI ^b	IC ₅₀	95% CI	IC ₅₀	95% CI	IC ₅₀	95% CI
<i>Rhizopus stolonifer</i>	8.7	(2, 15.4)	7.4	(3.2, 11.7)	22.1	(-14.7, 58.9)	12.4	(0.2, 24.5)
<i>Aspergillus flavus</i> AF70	3.9	(2.7, 5.1)	3.3	(2.2, 4.4)	7.9	(4.3, 11.6)	11.2	(0.8, 21.5)
<i>Aspergillus flavus</i> Tox 4	2.9	(2.3, 3.6)	2.4	(1.9, 3)	7.1	(5.1, 9)	9.8	(4, 15.6)
<i>Fusarium graminearum</i>	2.1	(1.7, 2.4)	2.2	(1.9, 2.5)	4.6	(3.1, 6.2)	6.2	(2.3, 10.2)
<i>Fusarium verticillioides</i>	2.1	(1.8, 2.4)	1.2	(1.1, 1.4)	2	(1.8, 2.3)	2.5	(2, 3)
<i>Fusarium oxysporum</i> f.s. vasinfectum	2.2	(1.8, 2.6)	1.5	(1.4, 1.7)	1.7	(1.5, 1.9)	2	(1.6, 2.4)
<i>Claviceps purpurea</i>	1.1	(1, 1.2)	1.1	(1, 1.2)	1.3	(1.1, 1.4)	1.6	(1.3, 1.8)
<i>Thielaviopsis basicola</i>	1.4	(1.3, 1.6)	1.3	(1.2, 1.3)	1.3	(1.1, 1.4)	1.5	(1.2, 1.7)
<i>Verticillium dahliae</i>	0.9	(0.8, 0.9)	0.8	(0.7, 0.9)	0.9	(0.9, 1)	0.8	(0.7, 0.9)
<i>Xanthomonas campestris</i> p.v. campestris	0.1	(0.1, 0.1)	0.1	(0.1, 0.1)	0.2	(0.2, 0.3)	0.2	(0.2, 0.3)
<i>Psuedomonas syringae</i> p.v. tabaci	0.1	(0.1, 0.1)	0.1	(0.1, 0.1)	0.1	(0.1, 0.2)	0.2	(0.2, 0.2)

Inhibitory dose 50 (IC₅₀) values for fungal and bacterial plant pathogens challenged with synthetic peptides, GV185, GV187, D4E1 and AGM182. Genvor peptides were plated on medium and viable spores or colonies were counted. Dose-response curves were estimated using a generalized linear model with logit link and binomial distribution, i.e. logistic regression. IC₅₀ values are the predicted peptide dose (μM) that 50% of spores or bacteria were inhibited or killed from dose-response curves for each synthetic peptide and pathogen with 95% confidence interval

Genvor's Proprietary Formulations Achieve Commercial-Grade Peptide Stability




Advanced formulation technology solves industry-wide peptide stability challenges, enabling 2+ year shelf life required for commercial agricultural markets

Genvor's Formulations are Market Ready:


- ✓ Industry-leading stability across multiple peptide candidates
- ✓ Meets agricultural industry standard for 2+ year shelf life
- ✓ Enables global distribution through existing supply chains
- ✓ Reduces storage and handling costs for partners
- ✓ Positions peptides as viable alternative to traditional fungicides

GV185



96% peptide retention after 2-year simulation

GV197



98% peptide retention after 2-year simulation

Third-Party Validation: Powering Progress Together



World-class partnerships accelerate technology development and de-risk commercialization

BAYER GOLDEN TICKET

Inaugural Recipient - 2024

First company selected for Bayer's Golden Ticket award:

- ✓ Year-long access to Bayer LifeHub California labs
- ✓ World-class mentorship resources
- ✓ Direct pathway to industry partnership



USDA CRADA

7+ year collaboration

Exclusive Cooperative R&D Agreement with USDA-ARS:

- ✓ Joint development of aflatoxin-resistant corn
- ✓ USDA co-assignment on key patents
- ✓ Fast-track regulatory pathway support



TUSKEGEE UNIVERSITY

Teaming Agreement - 2025

Strategic partnership with founding scientist institution:

- ✓ Access to world-class research laboratories
- ✓ Collaborative grant-supported development
- ✓ Next-generation scientific talent pipeline



TUSKEGEE
UNIVERSITY


Dual-Market Business Model Creates Multiple Revenue Pathways from a Single Platform



Genvor's BioCypher platform powers two commercialization strategies: a licensing-first model in agriculture and a direct-to-consumer model in human health and wellness

BioCypher™ Platform — One Technology Core

AGRICULTURE — Licensing-First Model



- ✓ **Global Scalability**
Accelerated through licensing, enabling efficient market entry & minimized overhead
- ✓ **De-Risked Innovation**
Built around market readiness, proven efficacy, and grower-driven outcomes
- ✓ **Flexible Licensing Model**
R&D reimbursement, milestone payments, and royalties on future sales

HUMAN HEALTH & WELLNESS — Direct-to-Consumer

Genvor brings targeted peptide-based recovery and performance solutions directly to consumers through strategic partnerships and retail channels.



- 🛒 **DTC Revenue Model**
Consumer-facing peptide products sold direct-to-consumer and through specialty retail channels
- 🤝 **Strategic Wellness Partnerships**
Credentialed wellness leaders who bring authentic credibility, market access, and deep recovery expertise
- 📈 **Higher-Margin Consumer Products**
OTC wellness positioning enables faster time-to-revenue

Proven Performance And IP Protection Validate Commercial Potential



Patent Portfolio Strength

First U.S. patent issued in 2015 covering eight peptides, including all key pipeline peptides.



Transgenic Protection Secured

Second U.S. patent issued in 2021 for transgenic corn with anti-fungal peptide AGM-182.





Expanding IP Coverage

Today, Genvor has 5 issued U.S. patents, 2 pending U.S. patent applications, and 4 additional applications in preparation.



Commercial Validation Progress

Already secured post-approval citrus licensing deal for AGM-176/179 with Tier-1 partner.



Experienced Team Brings Deep Industry Expertise



Agribusiness Leadership



Chad Pawlak Sr., MBA
Chief Executive Officer

Scientific Innovation



Jesse Jaynes, Ph.D.
Co-Founder, Chairman & Director of
Scientific Research & Development

Scientific Innovation



Clayton C. Yates, Ph.D.
Co-Founder, Scientific Advisor

Biologicals Leadership



George Stavrides, Ph.D.
EVP, Business Development &
Commercialization

AI/ML Expertise



Lance Culane, Ph.D.
Director of AI & Machine Learning

Communications Leadership



Carly Scaduto
Director of Corporate
Communications

Financial Leadership



Adrienne Anderson
Controller

Research Expertise



Brianna Fochs, Ph.D.
Senior Scientist & Lab Manager

genvor

genvor.com

